Dallas, Texas--(Newsfile Corp. - June 18, 2024) - Stonegate Healthcare Partners, a leading name in healthcare consultancy and market intelligence, is pleased to announce the publication of a comprehensive thematic report titled "Leading Innovations in Anti-Aging Dermatology." This report delves into the transformative advancements in the treatment of age-related skin conditions, focusing on cutting-edge technologies and personalized holistic approaches that are poised to revolutionize the skincare industry.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
About Stonegate Healthcare Partners
Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies.
Contacts:
Shiv Kapoor
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Stonegate Healthcare
Last Trade: | C$0.08 |
Daily Change: | 0.02 33.33 |
Daily Volume: | 91,999 |
Market Cap: | C$20.710M |
November 20, 2024 March 13, 2024 January 26, 2024 June 28, 2023 May 03, 2023 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB